To your last point, I remember discovering a large investment by Woodford and an investment group called Phase VI around the time of the Phase V report in the company that provides the imaging analysis for the trial. It came across as a way to get inside information or to insert employees who could access the trial information. We already know that is a play out of Woodford's game plan.
You are correct that I confused you with biosectinvestor who did in fact say that share price is irrelevant. It was not you, so I apologize for that. I guess we will see whether the trial is valid (or maybe we never will). I believe the preponderance of evidence suggests it is not. And still, no one wants to address the question of why they are doing a spring refresh if they plan to unblind in August. It doesn't make sense.